Cashu Logo
HomeWatchlistNewsSignalsPicks
DJI
+0.08%
SPX
-0.22%
IXIC
-0.51%
FTSE
-0.20%
N225
-0.22%
AXJO
-0.21%
Cashu Logo
Log In
HomeWatchlistNewsSignalsPicks
Stocks
0.00 (0.00%)
0.000
USD
At close at --,----
Cashu Logo Alt
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

  • About Us
  • Careers
  • Blog
  • News

Help & Support

  • Help Center
  • Contact Us
  • Pro Support

Legal

  • Privacy Policy
  • Terms of Use
InstagramYouTube

© 2024 Cashu PTY LTD.

Join our newsletter to keep up to date with us!

Overview

Loading chart...

Recently from Cashu

publisher logo
Cashu

Eli Lilly's Acquisition of Verve Therapeutics: Implications for Editas Medicine and Genetic Therapy

2 days ago
publisher logo
Cashu

Editas Medicine: Eli Lilly Acquires Verve Therapeutics for Cardiovascular Genetic Therapies

4 days ago
publisher logo
Cashu

Editas Medicine: Leading Genetic Innovation Amid Cultural and Ethical Considerations

4 months ago

Key Stats

Market Cap
184.21M
Dividend Yield
0.00%
P/E Ratio
-0.73
EPS
-2.88
Revenue
32.31M
Avg. Volume
1.50M

About

What does EDIT do?
Editas Medicine, headquartered in Cambridge, Massachusetts, specializes in genome editing technology and developed a proprietary CRISPR-based platform for transformative genomic medicines. Its lead program, reni-cel, aims to treat sickle cell disease and beta thalassemia.
Sector
💻 Health Care
IPO
CEO
Employees
Headquarters
Massachusetts, USA
Website
http://www.editasmedicine.com
Stocks
Health Care
edit
Editas Medicine
EDIT
-0.13 (-5.53%)
2.22
USD
At close at Jun 20, 20:41 UTC
Summary
News
Signals
Benchmarks
Financials